Dosing of Tissue Plasminogen Activator Often Differs from 0.9 mg/kg, but Does Not Affect the Outcome

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00069038" target="_blank" >RIV/00216224:14110/13:00069038 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00159816:_____/13:00060584

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2012.10.010" target="_blank" >http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2012.10.010</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2012.10.010" target="_blank" >10.1016/j.jstrokecerebrovasdis.2012.10.010</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Dosing of Tissue Plasminogen Activator Often Differs from 0.9 mg/kg, but Does Not Affect the Outcome

Popis výsledku v původním jazyce

Background: The safety and efficacy of low-and high-dose intravenous tissue plasminogen activator (t-PA) for the treatment of acute ischemic stroke are poorly understood. In this multicenter study, we examined the relationships between different doses oft-PA and outcome. Methods: Between 2006 and 2010, patients were enrolled if they were treated with t-PA on the basis of estimated body weight and on the subsequent availability of actual body weight. Based on the actual weight, patients were divided into lower (&lt;0.85 mg/kg), standard (0.85-0.95 mg/kg), and higher (&gt;0.95 mg/kg) t-PA dose groups. Differences in the outcomes of these groups were compared in terms of functional recovery (modified Rankin Scale [mRS] 0-1) at 3 months and the incidenceof parenchymal hemorrhages on follow-up computed tomographic scans. Results: This cohort study included 272 patients: 171 (63%) patients received the standard t-PAdose, 62 (23%) a lower dose, and 39 (14%) a higher dose.

Název v anglickém jazyce

Dosing of Tissue Plasminogen Activator Often Differs from 0.9 mg/kg, but Does Not Affect the Outcome

Popis výsledku anglicky

Background: The safety and efficacy of low-and high-dose intravenous tissue plasminogen activator (t-PA) for the treatment of acute ischemic stroke are poorly understood. In this multicenter study, we examined the relationships between different doses oft-PA and outcome. Methods: Between 2006 and 2010, patients were enrolled if they were treated with t-PA on the basis of estimated body weight and on the subsequent availability of actual body weight. Based on the actual weight, patients were divided into lower (&lt;0.85 mg/kg), standard (0.85-0.95 mg/kg), and higher (&gt;0.95 mg/kg) t-PA dose groups. Differences in the outcomes of these groups were compared in terms of functional recovery (modified Rankin Scale [mRS] 0-1) at 3 months and the incidenceof parenchymal hemorrhages on follow-up computed tomographic scans. Results: This cohort study included 272 patients: 171 (63%) patients received the standard t-PAdose, 62 (23%) a lower dose, and 39 (14%) a higher dose.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Stroke & Cerebrovascular Diseases

ISSN

1052-3057

e-ISSN

—

Svazek periodika

22

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

5

Strana od-do

1293-1297

Kód UT WoS článku

000327719000091

EID výsledku v databázi Scopus

—